The DCIS test is intended to be used for patients with early-stage (Stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy. You may be a candidate for the test if you have recently been diagnosed with ductal carcinoma in situ (DCIS), your surgery was performed as a lumpectomy and not as a mastectomy and, you and your doctor are making treatment decisions regarding future treatment. If you feel you may be eligible, speak with your doctor regarding the Oncotype DX test.
According to Dr. Rick Baehner, Senior Director of Pathology at Genomic Health, Inc., there is a large population eligible for the DCIS test.
No comments:
Post a Comment